InvestorsHub Logo
Followers 10
Posts 1244
Boards Moderated 0
Alias Born 10/12/2012

Re: Nomo123 post# 19292

Friday, 05/30/2014 10:42:50 AM

Friday, May 30, 2014 10:42:50 AM

Post# of 30990
Re your commentary:
"This is a REAL study not STSI garbage...
Notice how the results are talking about improving symptoms.
The STSI studies don't study symptoms... because they know those studies would expose anatabloc as a scam. JMHO"

The facts:
Anatabloc is a neutracutical that underwent a small clinical trial no different than a prescription drug would during phase 3 trials. Please tell me the names of other neutracuticals that have done the same? Anatabloc blocks the stimulation of NF-B, the cause of chronic inflammation. ("Thyroiditis is an inflammation (not an infection) of the thyroid gland." (from EndoCrine Web)) So, in fact, Anatabloc's mode of efficacy treats the cause rather than symptoms as you state. From the article: "The Bristol Myers drug clazakizumb in concert with another drug methotrexate showed efficacies equal to an existing drug by Humira." Please reread the excerpt again, carefully. The article shows that their drug treated improvement in symptoms, not cause. From the article:
"Bristol-Myers’s clazakizumab with methotrexate reduced their symptoms by at least 20 percent, the company said. That was twice the rate of patients who took only methotrexate, a generic treatment for the disease. Of patients taking methotrexate and Humira, AbbVie’s injectable drug that sold $9.27 billion last year, 76 percent had symptoms fall by at least 20 percent. " So Bristol Myer's drug just equaled an existing drug by AbbVie.

It is unusual that a neutracutical would take on a clinical trial, especially in an area where few drugs provide a reduction in anti-bodies. The clincal trials also state that: "Long-term studies are warranted to confirm these results"

You can reread the facts about the trial here:

ASAP trial: Anatabine decreased thyroid autoimmunity in Endocronology Today, Schmeltz LR. J ClinEndocrinolMetab.,November 6, 2013 at:
http://www.healio.com/endocrinology/thyroid/news/online/%7B288199cd-9fb4-46e7-8240-9de6a1346786%7D/asap-trial-anatabine-decreased-thyroid-autoimmunity

Your negative commentaries, while appreciated, should be based on facts and not on false assertations that are misleading. You should read a book: "Merchants of Doubt", it pretty much sums up your modus-operandi: "The U.S. scientific community has long led the world in research on such areas as public health, environmental science, and issues affecting quality of life. Our scientists have produced landmark studies on the dangers of DDT, tobacco smoke, acid rain, and global warming. But at the same time, a small yet potent subset of this community leads the world in vehement denial of these dangers. Merchants of Doubt tells the story of how a loose-knit group of high-level scientists and scientific advisers, with deep connections in politics and industry, ran effective campaigns to mislead the public and deny well-established scientific knowledge over four decades. Remarkably, the same individuals surface repeatedly-some of the same figures who have claimed that the science of global warming is "not settled" denied the truth of studies linking smoking to lung cancer, coal smoke to acid rain, and CFCs to the ozone hole. "Doubt is our product," wrote one tobacco executive. These "experts" supplied it. Naomi Oreskes and Erik M. Conway, historians of science, roll back the rug on this dark corner of the American scientific community, showing how ideology and corporate interests, aided by a too-compliant media, have skewed public understanding of some of the most pressing issues of our era." Your character description is similar to 'Fred Singer'

I recommend this book highly, you might get some ideas from it to improve your editorial skills.

BTW, you apparently did not read the posting #19261. I bring this to your attention-- "Calling all Cynics" at: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102589698

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.